Breaking News

Biofortuna Expands Immunoassay Services

Invests in production capabilities for immunoassay design, development and manufacture

Biofortuna is expanding its IVD service portfolio to provide more focus on immunoassay design, development and manufacture. The company has invested in its production capabilities to include plate coating, washing, drying and quality control, as well as a manufacturing suite for immunoassay kits.
 
This expansion was driven by current customer projects and increasing demand from the market. These enhanced manufacturing capabilities expand existing immunoassay services and offers increased flexibility to clients.
  
This focus on immunoassay products will complement Biofortuna’s molecular IVD services, which include ISO 13485 accredited and FDA registered contract research, lyophilization, air-drying, manufacturing, dispensing and kitting of diagnostic products.
 
Biofortuna’s chief executive officer, Dr. Simon Douglas, said, “The success and growth of current projects has fueled the desire to increase our immunoassay offering. This expansion will allow for large scale manufacturing of ELISA-based kits to meet our customers’ growing needs.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters